Home › Funds › TCG Crossover Management, LLC › DYN

TCG Crossover Management, LLC position in DYN

DYNE THERAPEUTICS INC · Health Care

TCG Crossover Management, LLC reported holding 4,615,144 shares of DYN (DYNE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$74.3M, representing 2.10% of its reported portfolio and ranking #19 among its reported holdings. TCG Crossover Management, LLC has disclosed DYN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)4.62M sh
Reported value held$74.35M
Portfolio Weight2.10%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How TCG Crossover Management, LLC's DYN position evolved

TCG Crossover Management, LLC first disclosed a stake in DYN in Q3 2023 at 1,650,150 shares (US$14.8M). The position peaked in Q2 2026 at 4,615,144 shares, worth US$102.5M. Across 13 filings, TCG Crossover Management, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 4,615,144 shares valued at US$74.3M. Notable position changes include a 61% increase in Q1 2024 (shares rose 24% over the following quarter), a 42% increase in Q2 2025 (shares rose 33% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.65M $14.79M New
Q4 2023 1.65M $21.95M Hold
Q1 2024 2.65M $75.24M Add
Q2 2024 2.65M $93.52M Hold
Q3 2024 2.65M $95.19M Hold
Q4 2024 2.65M $62.44M Hold
Q1 2025 2.65M $27.72M Hold
Q2 2025 3.77M $35.86M Add
Q3 2025 4.62M $58.38M Add
Q4 2025 4.62M $90.27M Hold
Q1 2026 4.62M $83.67M Hold
Q2 2026 4.62M $102.50M Hold
Q3 2026 4.62M $74.35M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in DYN — the largest reported positions include Vestal Point Capital, LP (US$75.0M), ORBIMED ADVISORS LLC (US$71.9M), Frazier Life Sciences Management, L.P. (US$70.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has TCG Crossover Management, LLC held DYN?

TCG Crossover Management, LLC has disclosed DYN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is TCG Crossover Management, LLC's current position in DYN?

As of Q3 2026, TCG Crossover Management, LLC holds 4.62M shares of DYN (DYNE THERAPEUTICS INC), valued at $74.35M, representing 2.10% of its reported portfolio and ranking #19.

Has TCG Crossover Management, LLC been buying or selling DYN?

In the latest 13F filing (Q3 2026), TCG Crossover Management, LLC held unchanged its position in DYN. The position peaked in Q2 2026 at 4.62M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Vestal Point Capital, LP, ORBIMED ADVISORS LLC, Frazier Life Sciences Management, L.P., among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.